Roberti Maria Paula, Rauber Conrad, Kroemer Guido, Zitvogel Laurence
Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany.
Department of Gastroenterology and Infectious Diseases, Heidelberg University Hospital (UKHD), Heidelberg, Germany.
Semin Cancer Biol. 2022 Nov;86(Pt 2):955-966. doi: 10.1016/j.semcancer.2021.09.016. Epub 2021 Oct 5.
Besides tumor cell-intrinsic oncogenic pathways, host and environmental factors have a major impact on cancer immunosurveillance and the efficacy of immunotherapeutics. Several modalities of anticancer treatments including immunogenic chemotherapies and immune checkpoint inhibitors lose their efficacy in patients treated with broad-spectrum antibiotics, pointing to a key role for the gut microbiota. The complex interactions between intestinal microbes, gut immunity and anti-tumor responses constitute an emerging field of investigation. In this work, we revise key primary literature, with an emphasis on recent mechanistic insights, unraveling the interplay between the immunosurveillance of colon cancers and ileal factors including the local microbiota, tissue architecture and immune system.
除了肿瘤细胞内在的致癌途径外，宿主和环境因素对癌症免疫监视及免疫治疗的疗效也有重大影响。包括免疫原性化疗和免疫检查点抑制剂在内的几种抗癌治疗方式，在接受广谱抗生素治疗的患者中会失去疗效，这表明肠道微生物群起着关键作用。肠道微生物、肠道免疫和抗肿瘤反应之间的复杂相互作用构成了一个新兴的研究领域。在这项工作中，我们回顾了关键的原始文献，重点是最近的机制见解，揭示了结肠癌免疫监视与包括局部微生物群、组织结构和免疫系统在内的回肠因素之间的相互作用。
